EOLS News and Press, Evolus Inc. From 11/05/25

2025-11-05 16:42:39 ET More on Evolus Seeking Alpha’s Quant Rating on Evolus Historical earnings data for Evolus Financial information for Evolus Read the full article on Seeking Alpha For further details see: Evolus GAAP EPS of -$0.24 beat...

Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau ® Net Revenue of $63.2 Million for Q3 2025, Up from $59.7 Million in Q2 2025, Reflecting Sequential Growth That Outperformed Typical Seasonal Trends Evolysse &...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Stifel Healthcare Conference. The fireside c...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Evolus managemen...

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch PR Newswire Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (...

2025-09-08 08:58:38 ET More on Evolus Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings Evolus plunges after Q2 miss, guidance cut; Needham downgrades Evolus outlines $700M 2028 revenue target and cost realignment amid market softness Read the full article...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and oper...

Evolysse ™ Sculpt met the primary endpoint of non-inferiority and demonstrated statistical superiority to Restylane ® -Lyft The safety profile was similar between Evolysse ™ Sculpt and Restylane ® -Lyft and no treatment-related serious adverse event...